Special Issue

Antimicrobial Mechanism and Enlightenment to New Antimicrobial Agents

Message from the Guest Editors

The increased emergence of antimicrobial resistance (AMR) is a major healthcare problem worldwide. Understanding the mechanisms and drivers of AMR will provide a scientific basis and strategy to combat the threat to human health and biosecurity from AMR. In addition, AMR necessitates the development of novel antimicrobial agents with different mechanisms of action from traditional antibiotics. These alternatives include natural products (e.g., flavonoids, phytochemicals, and polysaccharides), phage and phage-derived endolysins, vaccines, probiotics, antibodies, peptides, and other solutions. The aim of this Special Issue is to present the status of and future trends in tracking antimicrobial mechanism and the enlightenment for new antimicrobial agents. Manuscripts about antimicrobial mechanisms, the discovery of novel antimicrobial agents, new methods for AMR surveillance, diagnosis, and antimicrobial screening, experimental therapy of antimicrobial agents in vitro and in vivo, and the antibacterial, antibiofilm, and antifungal applications of these agents in the related field of microbiology, biotechnology, and pharmacology are welcome for submission.

Guest Editors

Prof. Dr. Hang Yang

Prof. Dr. Daniel C. Nelson

Prof. Dr. Krystyna Dąbrowska

Deadline for manuscript submissions

closed (31 October 2022)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/108374

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

